Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q2 2024 Earnings Presentation
17 slides from Sanara Medtech's earnings presentation, Aug 12, 2024
Slide 1: Q2 2024 Earnings and Business Update Call
Q2 2024 Earnings and Business Update Call August 13, 2024 Sanara MedTech Evidence Based Healing ~*~ 9 5 65646 6 6G o ee ce © e oe ee e © e e© © *& ° ee e e© e e © *& ° ° ° ° o e e e e © °°
Slide 2: Disclaimers
MedTech Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All stateme
Slide 3: Executive Summary
Sanara MedTech Executive Summary + Financial Update (Unaudited) + Highest net revenue quarter in the Company's history ($20.2 million) + Eleventh consecutive record revenue quarter « Net loss of $3.5 million in Q2 * Adjusted EBITDA” of $0.6 million in Q2 * Non-Core Operations Expenses in Q2 ¢ Prior
Slide 4: Surgical Sales Overview
Surgical Sales Sales Overview (Unaudited) Sanara products were sold in over 1,100 hospitals/ASCs across 34 states plus the District of Columbia‘) in the TTM ended June 30, 2024. Sanara products were contracted or approved to be sold in more than 4,000 hospitals/ASCs as of June 30, 2024. 300+ distrib
Slide 5: Surgical Growth Opportunities
Surgical Growth Opportunities Additional Facility Approvals * Recently executed a contract with a national GPO giving SMTI sales team access to an additional 1,000+ facilities. * Team is working to further penetrate existing facilities while also generating sales in new facilities. Additional Specia
Slide 6: Operational Alignment
Sanara MedTech Operational Alignment Reorganized operations team to centralize ownership and accountability across all aspects of customer support, product fulfillment, and underlying IT system infrastructure. IT/Infrastructure * Building out IT Roadmap focused on workflow automation and digital sup
Slide 7: Tissue Health Plus
Tissue Health Plus
Slide 8: Wound Care Represents $100B+ Yearly Spend
Wound Care Represents $100B+ Yearly Spend (Products + Services) But Generates Mixed Patient Outcomes Opportunity Reduce hospital spend by realigning home & community based wound care (physician offices, skilled nursing homes) (1) THP Analysis + Carter MJ, DaVanzo J, Haught R, et al. Chronic wound pr
Slide 9: Our Program is Designed to Align Patients, Payors and Providers
Our Program is Designed to Align Patients, Payors 3% Sanara And Providers To Deliver Compelling Value vane” MedTech Aligned Value Delivery Programs Tailored For Payor’s Specific Population Accrual Of Hospital Based Savings (>20%) To Payor Payor Net Savings 2X to 5X THP Fees Two-Way Integration Compl
Slide 10: Q2 2024 Financial Highlights (Unaudited)
Q2 2024 Financial Highlights (Unaudite Revenue For the three months ended June 30, 2024, Sanara generated net revenue of $20.2 million compared to net revenue of $15.8 million for the three months ended June 30, 2023, a 28% increase from the prior year period. The higher net revenue for the three mo
Slide 11: Q2 2024 Financial Highlights (Continued)
Q2 2024 Financial Highlights (Continued) R&D Expenses (continued) R&D expenses included $0.4 million and $1.0 million attributable to our THP segment for the three months ended June 30, 2024 and 2023, respectively. The lower R&D expenses for the three months ended June 30, 2024 compared to the three
Slide 12: Segment Reporting
Segment Reporting * Segment Reporting Overview + Break out of Tissue Health Plus and Sanara Surgical to inform the investor community of our strategic rationale of the acute/post acute comprehensive strategy investments. Three Months Ended June 30, 2024 Net Revenue Net loss $(2.2) $(1.3) $(3.5) Segm
Slide 13: CRG Facility
CRG Facility Strategic Rationale * Non-dilutive to equity holders and it provides growth/acquisition capital as well as strengthens our cash position. * Flexible capital that can be drawn at the Company’s option. * Allows for Sanara to enter into a separate $10.0 million revolver backed by A/R and i
Slide 14: Questions
“4 Questions = Sanara MedTech Evidence Based Healing
Slide 15: Appendix
Appendix 2%. Sanard * MedTech Evidence Based Healing
Slide 16: Non-GAAP Financial Measure
. . Sanara Non-GAAP Financial Measure MedTech Use of Non-GAAP Financial Measure To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release
Slide 17: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation (Consolidated) of GAAP to No -GAAP Financial Measures ‘Three Months Ended June 30, 2024 2023 Sanara Surgical TH Total Sanara Surgical THP Total Net Income (Loss) $ 2214313) $ (1,314,889) $ (3,529,202) $ 95,098 $ (1,961,278) $ (1,866,180) Adjustments: Interest expense 644,346 = 644,346